Alzheimer’s Disease and Epilepsy: Exploring Shared Pathways and Promising Biomarkers for Future Treatments
Journal of Clinical Medicine,
Год журнала:
2024,
Номер
13(13), С. 3879 - 3879
Опубликована: Июль 1, 2024
Background:
Alzheimer's
disease
(AD)
and
epilepsy
represent
two
complex
neurological
disorders
with
distinct
clinical
manifestations,
yet
recent
research
has
highlighted
their
intricate
interplay.
This
review
examines
the
association
between
AD
epilepsy,
particular
emphasis
on
late-onset
of
unknown
etiology,
increasingly
acknowledged
as
a
prodrome
AD.
It
delves
into
epidemiology,
pathogenic
mechanisms,
features,
diagnostic
characteristics,
treatment
strategies,
emerging
biomarkers
to
provide
comprehensive
understanding
this
relationship.
Methods:
A
literature
search
was
conducted,
identifying
128
relevant
articles
published
2018
2024.
Results:
Findings
underscore
bidirectional
relationship
indicating
shared
pathways
that
extend
beyond
traditional
amyloid-beta
Tau
protein
pathology.
These
encompass
neuroinflammation,
synaptic
dysfunction,
structural
network
alterations,
well
molecular
mechanisms.
Notably,
epileptic
activity
in
patients
may
exacerbate
cognitive
decline,
necessitating
prompt
detection
treatment.
Novel
biomarkers,
such
subclinical
epileptiform
detected
via
advanced
electroencephalographic
techniques,
offer
promise
for
early
diagnosis
targeted
interventions.
Furthermore,
therapeutic
approaches
targeting
mechanisms
hold
potential
modification
both
epilepsy.
Conclusions:
highlights
importance
providing
insights
future
directions.
Clinical
data
methods
are
also
reviewed,
enabling
clinicians
implement
more
effective
strategies.
Язык: Английский
Serotonin in Depression and Alzheimer’s Disease: Focus on SSRI’s Beneficial Effects
Jihane Tahiri,
Maamoon Mian,
Fatima Aftan
и другие.
Ageing Research Reviews,
Год журнала:
2024,
Номер
101, С. 102537 - 102537
Опубликована: Окт. 9, 2024
Язык: Английский
Blood-derived mitochondrial DNA copy number is associated with Alzheimer disease, Alzheimer-related biomarkers and serum metabolites
Alzheimer s Research & Therapy,
Год журнала:
2024,
Номер
16(1)
Опубликована: Окт. 23, 2024
Blood-derived
mitochondrial
DNA
copy
number
(mtDNA-CN)
is
a
proxy
measurement
of
function
in
the
peripheral
and
central
systems.
Abnormal
mtDNA-CN
not
only
indicates
impaired
mtDNA
replication
transcription
machinery
but
also
dysregulated
biological
processes
such
as
energy
lipid
metabolism.
However,
relationship
between
Alzheimer
disease
(AD)
unclear.
We
performed
two-sample
Mendelian
randomization
(MR)
using
publicly
available
summary
statistics
from
GWAS
for
AD
to
investigate
causal
AD.
estimated
whole-genome
sequence
data
blood
brain
samples
13,799
individuals
Alzheimer's
Disease
Sequencing
Project.
Linear
Cox
proportional
hazards
models
adjusting
age,
sex,
study
phase
were
used
assess
association
with
The
biomarkers
serum
metabolites
was
evaluated
Neuroimaging
Initiative
linear
regression.
conducted
mediation
analysis
test
natural
indirect
effects
change
on
risk
through
significantly
associated
metabolites.
MR
suggested
decreased
blood-derived
increased
(OR
=
0.68;
P
0.013).
Survival
showed
that
higher
conversion
mild
cognitive
impairment
(HR
0.80;
0.002).
identified
significant
associations
FDG-PET
(β
0.103;
0.022),
amyloid-PET
0.117;
0.034),
CSF
amyloid-β
(Aβ)
42/40
(β=-0.124;
0.017),
t-Tau
0.128;
0.015),
p-Tau
0.140;
0.008),
plasma
NFL
0.004)
females.
Several
species,
amino
acids,
biogenic
amines
mtDNA-CN.
Causal
analyses
about
third
effect
mediated
by
(P
0.009),
this
more
females
<
0.005).
Our
measured
predictive
including
particularly
Further,
we
illustrate
possibly
increases
dysregulation
metabolism
inflammation.
Язык: Английский
Qiangji Decoction mitigates neuronal damage, synaptic and mitochondrial dysfunction in SAMP8 mice through the regulation of ROCK2/Drp1-mediated mitochondrial dynamics
Journal of Ethnopharmacology,
Год журнала:
2025,
Номер
unknown, С. 119424 - 119424
Опубликована: Янв. 1, 2025
Язык: Английский
The role and therapeutic potential of mitophagy in major depressive disorder
Frontiers in Pharmacology,
Год журнала:
2025,
Номер
16
Опубликована: Март 26, 2025
Major
depressive
disorder,
also
known
as
MDD,
affects
more
than
264
million
people
globally,
making
it
a
prevalent
and
critical
health
challenge.
Traditional
treatments
show
limited
efficacy
in
many
patients.
Therefore,
exploring
new
treatment
methods
is
particularly
crucial.
Mitophagy,
regulatory
process,
can
help
understand
treat
MDD.
This
paper
focuses
on
the
molecular
mechanisms
of
mitophagy,
starting
from
proteins
related
pathways,
its
role
The
study
explores
associations
between
mitophagy
neuroinflammation,
oxidative
stress,
neurotransmitter
synthesis,
neuroplasticity
MDD
discusses
progress
clinical
research
In
addition,
article
describes
current
pharmaceutical
non-pharmaceutical
interventions
that
regulate
unravels
potential
challenges
these
therapeutic
strategies
settings.
offers
deeper
insight
into
pathogenesis
scientific
basis
for
development
strategies.
Язык: Английский
Biological Profile of Synthetic and Natural Indole Derivatives: Paving New Paths in Cancer Treatment
Drugs and Drug Candidates,
Год журнала:
2024,
Номер
3(3), С. 488 - 511
Опубликована: Июль 19, 2024
The
indole
scaffold
is
considered
a
privileged
framework
in
the
design
and
synthesis
of
several
active
pharmaceutical
ingredients,
particularly
as
promising
anticancer
agents.
Its
presence
bioactive
natural
compounds
has
caught
attention
scientific
community,
which
been
committed
to
unveiling
its
biosynthetic
pathways
generating
multiple
derivatives
with
innovative
synthetic
routes.
large
variety
structural
enhances
their
use
bioapplications
pharmacological
activities.
In
this
review,
reader
will
have
easy
access
some
examples
antimicrobial,
antidepressant,
anti-inflammatory,
antiviral,
antimigraine,
antiemetic
activity.
However,
main
topic
review
related
cancer
importance
drugs.
Two
reasons
why
massive
problem
worldwide
are
attributed
struggle
develop
target-specific
drugs
while
avoiding
drug
resistance.
Among
countless
targeting
specific
proteins
involved
tumorigenesis,
prompting
life
quality
treatment
types,
protein
kinases,
desoxyribonucleic
acid
topoisomerases,
P-glycoprotein
shown
be
targets
when
it
comes
development
novel
Furthermore,
also
studied
regarding
affinity
other
cancer.
This
aims
highlight
utility
design,
inspiring
creation
new
that
target
address
resistance
challenges.
Язык: Английский
From Fundamentals to Innovation in Alzheimer’s Disease: Molecular Findings and Revolutionary Therapies
Mădălina Georgeta Sighencea,
R. Popescu,
Simona Trifu
и другие.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(22), С. 12311 - 12311
Опубликована: Ноя. 16, 2024
Alzheimer's
disease
(AD)
is
a
global
health
concern
and
the
leading
cause
of
dementia
in
elderly.
The
prevalence
this
neurodegenerative
condition
projected
to
increase
concomitantly
with
increased
life
expectancy,
resulting
significant
economic
burden.
With
very
few
FDA-approved
disease-modifying
drugs
available
for
AD,
there
an
urgent
need
develop
new
compounds
capable
impeding
progression
disease.
Given
unclear
etiopathogenesis
review
emphasizes
underlying
mechanisms
condition.
It
explores
not
only
well-studied
aspects,
such
as
accumulation
Aβ
plaques
neurofibrillary
tangles,
but
also
novel
areas,
including
glymphatic
lymphatic
pathways,
microbiota
gut-brain
axis,
serotoninergic
autophagy
alterations,
vascular
dysfunction,
metal
hypothesis,
olfactory
pathway,
oral
health.
Furthermore,
potential
molecular
targets
arising
from
all
these
have
been
reviewed,
along
promising
approaches
nanoparticle-based
therapy,
neural
stem
cell
transplantation,
vaccines,
CRISPR-Cas9-mediated
genome
editing
techniques.
Taking
into
account
overlap
various
mechanisms,
individual
combination
therapies
emerge
future
direction
AD
strategy.
Язык: Английский
The 40 Hz flickering light restores synaptic plasticity and mitochondrial phenotype in experimental model of Alzheimer’s disease
bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Май 15, 2024
Abstract
Alzheimer’s
disease
(AD)
is
the
most
prevalent
form
of
dementia
and
a
public
health
priority.
The
causes
AD
are
not
completely
understood.
Pathogenetic
factors
including
mitochondrial
dysfunction,
oxidative
stress,
reduced
energy
status,
compromised
ion
channels
contribute
to
onset
progression
disease.
Flickering
light
therapy
in
experimental
clinical
has
shown
promising
outcomes.
However,
mechanisms
behind
effect
flickering
at
molecular
cellular
level
yet
been
fully
investigated.
In
this
study,
we
established
streptozotocin
(STZ)-induced
models
by
intracerebroventricular
(ICV)
injection
STZ
Wistar
rats
monitored
their
memory
decline.
Sham
were
either
exposed
or
40
Hz
for
7
consecutive
days
after
injection.
Memory
cognition-related
behavioral
analysis,
pathological,
electrophysiological,
biochemical
assessment
brain
tissue,
function
assays
conducted
treatment.
Cognitive
impairment,
examined
Morris
water
maze
(MWM),
novel
object
recognition
(NOR),
passive
avoidance
(PA)
test,
was
observed
STZ-induced
treatment
improved
these
behaviors.
led
significant
accumulation
reactive
oxygen
species
(ROS)
amyloid
beta
(Aβ),
decreased
serotonin
dopamine
levels,
respiration.
reversed
all
parameters
group.
synaptic
plasticity
severely
affected,
but
prevented
loss
activity
light-treated
rats.
Additionally,
white
elevated
levels
metabolites
current
possible
opening
calcium-sensitive
potassium
(mitoBK
Ca
)
channel
which
significantly
downregulated
rat
neurons.
restored
neurons
cognition
animals;
therefore,
it
can
be
strategy
reduce
progression.
Язык: Английский
40 Hz light preserves synaptic plasticity and mitochondrial function in Alzheimer’s disease model
Scientific Reports,
Год журнала:
2024,
Номер
14(1)
Опубликована: Ноя. 6, 2024
Alzheimer's
disease
(AD)
is
the
most
prevalent
type
of
dementia.
Its
causes
are
not
fully
understood,
but
it
now
known
that
factors
like
mitochondrial
dysfunction,
oxidative
stress,
and
compromised
ion
channels
contribute
to
its
onset
progression.
Flickering
light
therapy
has
shown
promise
in
AD
treatment,
though
mechanisms
remain
unclear.
In
this
study,
we
used
a
rat
model
streptozotocin
(STZ)-induced
evaluate
effects
40
Hz
flickering
therapy.
Rats
received
intracerebroventricular
(ICV)
STZ
injections,
7
days
after,
they
were
exposed
for
15
min
daily
over
seven
days.
Cognitive
memory
functions
assessed
using
Morris
water
maze,
novel
object
recognition,
passive
avoidance
tests.
STZ-induced
rats
exhibited
cognitive
decline,
elevated
reactive
oxygen
species,
amyloid
beta
accumulation,
decreased
serotonin
dopamine
levels,
impaired
function.
However,
prevented
these
effects,
preserving
function
synaptic
plasticity.
Additionally,
restored
metabolites
normalized
ATP-insensitive
calcium-sensitive
potassium
(mitoBKCa)
channel
activity,
which
was
otherwise
downregulated
rats.
Our
findings
suggest
could
be
promising
treatment
neurodegenerative
disorders
by
Язык: Английский